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Abstract
Background: Liver dialysis, molecular adsorbent recirculating system (MARS) particularly, has been
used in liver failure to bridge to transplantation.

We expanded the indication for MARS to patients with

acute shock liver failure and cardiopulmonary failure on ECMO, aiming to improve survival to wean
from ECMO.
Methods:

An IRB approved, retrospective chart analysis of patients on ECMO between 2010 and 2015

found 28 patients who met the criteria for acute liver failure, diagnosed by hyperbilirubinemia (total
bilirubin ≥ 10 mg/dl), or by elevated transaminase (alanine transaminase [ALT] >1000 IU/L). Among
those, 14 patients underwent MARS treatment (Group M) and 14 patients were supported with optimal
medical treatment without MARS (Group C).

Patient characteristics, liver function and survival were

compared between groups.
Results:
groups.

Demographics, clinical risk factors, and pre-ECMO laboratory data were identical between the
MARS was utilized continuously for 8 ± 9 days in Group M.

Total bilirubin, ALT, and

international normalized ratio (INR) were improved significantly in Group M. There were no
MARS-related complications.

Survival to wean from ECMO for Group M was 64% (9/14) versus 21%

(3/14) for Group C, p = 0.02.

Death related to worsening liver dysfunction during ECMO was 40% (2/5

deaths) in Group M and 100% (11/11 deaths) in Group C, p=0.004. Thirty-day survival after ECMO
was 43% (6/14) in Group M and 14% (2/14) in Group C, p=0.09.
Conclusions: MARS therapy on ECMO patients safely accelerated recovery of liver function and
improved survival to wean from ECMO, without increasing complications.
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Introduction
In cases of acute-on-chronic liver failure, liver dialysis, specifically the molecular adsorbent
recirculating system (MARS) has been used to bridge patients to liver transplantation and is known to
improve outcomes of liver transplantation.

1, 2

MARS therapy consists of filtering blood through a

specialized albumin-containing dialysate to remove protein-bound toxins.

Blood is filtered in-line

through a charcoal column and an anion exchanger column before return. This system allows for the
removal of molecules such as bile acids, bilirubin, and cytokines, as well as water-soluble toxins such as
creatinine and ammonia.

3

By removing both protein-bound and water-soluble toxins, MARS facilitates

liver recovery and also may prevent further deterioration of other organ systems.
Overall ECMO mortality is reported to be 47%-61%,

5

4

and one of the primary causes of death

for extracorporeal membrane oxygenation (ECMO) patients is refractory multiple-organ failure including
acute liver failure. Acute liver failure (ALF) occurs in ~13-19% of the ECMO population.

6

In our

institution, we expanded the indication for MARS to another patient population – cardiopulmonary failure
patients requiring ECMO who have developed acute liver failure.

This retrospective study was

performed to evaluate the questions: can MARS improve acute liver failure on ECMO safely, and to
evaluate the survival of the patients with or without MARS treatments on ECMO.
Methods
After approval from the institutional review board, medical records of consecutive ECMO
patients between August 2010 and March 2015 were retrospectively reviewed to identify the incidence of
liver dysfunction while on ECMO. The only exclusion criterion was any ECMO patient in whom
treatment was deemed futile within the first 24 hours of cannulation.
was primarily used for refractory cardiac failure,
used for refractory respiratory failure,

8

7

Veno-arterial ECMO (VA ECMO)

and veno-veno ECMO (VV ECMO) was primarily

detailed in the previous publications.

Among the 133 ECMO patients during the study period, 28 patients (21%) were found to have
acute liver failure, defined as total bilirubin ≥ 10 mg/dl or alanine aminotransferase (ALT) ≥ 1000 IU/L.
Further details for inclusion data are shown in Table 1. These patients were included if they met the
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criteria for liver failure despite correction of an underlying process such as hemolysis or obstructive
cholangitis. The rounding attending physician made the decision for the initiation of MARS. Of the 28
studied patients, 14 patients (Group M) underwent liver dialysis using MARS (Gambro, Lakewood, CO,
USA), and 14 patients (Group C) were supported with optimal medical therapies. Medical therapies for
Group C and Group M included maintenance of appropriate ECMO flow (body surface area x 2.2 L/min
or above), lactulose treatment, nutrition support (via either enteral tube feeding or total parenteral
nutrition), and avoidance of hepatotoxic medications, including statins and Amiodarone. In Group M,
the MARS system was run with blood flow rates between 100 – 150 ml/min using a standard dual lumen
dialysis catheter placed in the femoral vein, using a 25% albumin dialysate. Treatment was continued
until recovery of liver function; specifically, total bilirubin returned to ≤ 7 mg/dl and/or ALT ≤ 500 IU/L,
or the time of ECMO removal.

No patient was placed on MARS with the intention to bridge to liver

transplantation. The MARS circuit was maintained continuously, excepting for circuit changes needed
every 24 hours. Anticoagulation was maintained for a PTT between 45-55 seconds for ECMO
regardless the presence of MARS.
Primary study endpoints were survival to wean from ECMO and 30-day survival after ECMO
decannulation.

A secondary endpoint was the trend of liver function (total bilirubin, alanine

aminotransferase [ALT], and international normalized ratio [INR]) during treatments. In addition,
bleeding complications and disseminated intravascular coagulopathy (DIC) were monitored during
ECMO.
Data were expressed as number with percent and mean with standard deviations. Statistical
analysis consisted of two group comparisons between Group M and Group C using Student t-tests for
continuous variables and chi-square or Fisher's exact tests for categorical variables. A p-value less than
0.05 was considered to be significant.
Results
There were 14 patients in Group M and 14 patients in Group C.

Baseline characteristics,

pre-ECMO clinical risk factors, and laboratory data were compared and were similar between the two
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groups (Table 2).

Group C and Group M both include patients from overlapping timeframes – Group C

was not from an era prior to availability of MARS therapy.
The laboratory values for the patients at the time criteria of acute liver failure were met are shown
in Table 3. MARS therapy was initiated in mean of 5 ± 4 days after ECMO was started in Group M.
The length of ECMO before the patients met the criteria for acute liver failure in Group C was 7 ± 6 days.
The average length of MARS on ECMO was 8 ± 9 days (range 1 – 32 days).

After 3 days, total bilirubin

average for Group M (n=12) decreased by 5.1 ± 12 mg/dL, while Group C (n=9) average total bilirubin
increased 2.6 ± 9 mg/dl (p = 0.11).

By day 7, the average total bilirubin for Group M (n=11) had

decreased by 7.9 ± 15 mg/dL, while in the same time period the average bilirubin for Group C had
increased by 7.5 ± 6 mg/dL (p = 0.01). By day 3, ALT for Group M had decreased by 1310 ± 1851 IU/L
while in Group C the ALT had increased by 320 ± 733 IU/L (p = 0.01). Similarly, by day 3, INR for
Group M had decreased by 0.32 ± 0.5 while in Group C the INR had only decreased by 0.05 ± 0.4 IU/L (p
= 0.19). These trends are shown in Figure 1. Furthermore, these trends continued for the duration of
ECMO, as shown in Figure 2.
Bleeding complications while on ECMO, defined as bleeding that required invasive intervention,
were 79% (n=11) in both groups. The most common etiologies were gastrointestinal bleeding, epistaxis,
and cannula site bleeding; this breakdown was consistent across both groups.

Incidence of disseminated

intravascular coagulopathy (DIC) was 14% (n=2) for Group M vs. 21% (n=3) for Group C (p = 0.62).
The causes of DIC were multifactorial, and did not appear to be related to MARS treatment. There was
no MARS-related sepsis. There were no mechanical ECMO complications, such as flow competition,
during MARS.
Survival to wean from ECMO was 64% (9/14) in Group M and 21% (3/14) in Group C, p=0.02
(Figure 3). Death related to worsening liver dysfunction was 40% (2/5 deaths) in Group M and 100%
(11/11 deaths) in Group C (p=0.004).

Of the patients to survive to wean off of ECMO, only 2 patients

(22%) in Group M continued MARS treatment and in both of those cases, liver function was eventually
normalized. Five patients (56%) in Group M weaned to a permanent mechanical circulatory support
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device, versus only 1 patient (33%) in Group C (p=0.06). Thirty days survival after ECMO
decannulation was 43% (6/14) in Group M and 14% (2/14) in Group C, p=0.09 (Figure 3). The patients
in Group M who survived to wean off of ECMO all recovered liver function, therefore liver failure was
not a contributing factor to their death.
Discussion
The research on MARS for patients with cardiopulmonary failure requiring ECMO is very sparse.
Zitterman

9

used MARS for liver failure due to cardiogenic shock following cardiac surgery.

The study

involved 197 post-operative patients with a bilirubin > 6 mg/dl, of which 20 (10%) required ECMO.
They reported many complications (gastrointestinal, respiratory, and infections) and had an in-hospital
mortality rate of 66% (n=129) after MARS initiation. Total bilirubin did not decrease in their cohort
overall, though the survivors did show a significant decrease compared with non-survivors.

Based on

APACHE II, SOFA, and SAPS II scores, they determined a predicted mortality of 100%, which improved
to 34% (n=68) with MARS usage. 9 Survival within the ECMO population specifically was not
discussed.

In the only study specifically involving ECMO patients, Peek 10reviewed their series of

ECMO prior to the use of MARS and found that no ECMO patients at their institution survived once
severe liver dysfunction (total bilirubin > 23 mg/dl) developed and only 10% survived if bilirubin was
greater than 17 mg/dl.

With this prior survival data, Peek et al. changed their indication to initiate

MARS to include patients with bilirubin greater than 17 mg/dl.

Using MARS with this indication, 2/5

(40%) of the patients survived, compared to a prediction of 100% mortality. 10
While we were able to show that survival was improved in Group M versus Group C, it is equally
important to note that complications from using the treatment did not arise. In the two cases of DIC
within the treatment group, the causes were multifactorial, and did not appear to be related to MARS.
One of the patients was an acetaminophen overdose who was never stabilized following cardiac arrest and
ECMO, while the other was due to possible hemolysis after a prolonged course on ECMO requiring three
different mechanical circulatory support devices.

Complications occurring in the ICU course for both
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groups were similar, and specifically, incidence of DIC was similar, with no indication MARS was the
cause of any case of DIC.
In another study, Rittler11 reviewed 5 patients after Whipple’s operation or liver transplantation
complicated with liver failure and gram-negative sepsis and/or fungemia.

In that particular population

with liver failure accompanied by sepsis, despite the use of MARS, no patients survived.

They also

reported significant bleeding side effects in this group, although they were using heparin to maintain PTT
> 50 seconds to anti-coagulate the MARS system.

They concluded that sepsis-related liver failure might

not be an indication for MARS therapy. 11 In our study, sepsis was not the primary cause of shock liver,
but 2 patients in Group M (14%) and 3 patients in Group C (21%) were septic during the study. The
patients in Group M did not have any of the complications seen in the Rittler study.

Those 2 patients in

Group M survived, while none of the 3 septic patients in Group C survived to wean off of ECMO (p =
0.03).
Prior studies on the effectiveness of MARS in the acute-on-chronic liver failure population have
found that treatment can improve hemodynamic status or have an effect on coagulation.1,12 We found an
improvement of INR while on MARS (Figures 1 & 2); however, we were not able to identify the
hemodynamic improvement, maybe because hemodynamics were already supported by ECMO.
Our study supports that acute liver failure during ECMO can be supported with MARS and that
once liver functions are normalized, no additional MARS are necessary.

Additionally, the fact that five

of the patients in Group M were implanted with ventricular assist devices points to recovery of end organ
function, without any neurological deficits.

Without recovery of liver function, these patients would not

have been device candidates.
The decision to start MARS treatment was most often based upon increased total bilirubin.
However, we found the Group M had significantly higher liver enzymes as well. Group M also met
criteria for acute liver failure sooner after ECMO initiation (3 ± 3 days) than Group C (6 ± 7 days). By
day 3 after inclusion, only 70% (10/14) of the patients in Group C were alive, dropping to 36% (5/14)
survival by day 7.

This is compared to 79% (11/14) survival to day 7 in Group M (p=0.02). This
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illustrates that medical therapy alone is not enough to stop the progression from acute liver failure to
death in this patient population.

All patients in the treatment group showed total bilirubin that trended

downward by day 3, and continued downward until MARS was stopped (Figure 2) - suggesting that liver
function recovered.
The main limitation of this study was small sample size, retrospective, single center
experience. The decision to initiate MARS therapy was a clinical judgment base on the attending
physician’s assessment at the bedside and thus the two groups were not randomized.
not address discharge survival data.

This study does

Because many surviving patients in Group M went on to receive

permanent mechanical circulatory support devices, they required a more prolonged hospital stay. Survival
to discharge data in that group would have many other confounding variables from those other forms of
mechanical support devices as well as from the prolonged hospital stay.

Going forward, research is

needed to further refine the appropriate patient selection criteria and to initiate optimal treatment
guidelines, as well as to determine if MARS therapy increases survival to discharge.
Study Highlights
At this time, the use of MARS liver dialysis for acute-on-chronic liver failure to prolong
survival until transplantation has been accepted. 1,2 However, the research on expanding the use of
MARS to other patient populations has demonstrated mixed results, regarding both safety and efficacy.
This study looked at a specific population – multiple-organ failure patients on ECMO with acute liver
failure – in order to determine if MARS could improve survival to wean off ECMO.

The results showed

that without increasing complications, MARS could safely improve survival outcomes and accelerate
liver recovery within this patient population. ECMO is widely used to support the patient while the heart
and/or lungs recover, the results of this study indicate that the liver can recover in the same manner if the
patient is supported with the MARS liver dialysis system.
Conclusion
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The results of this study show that the MARS system for liver dialysis can safely and
effectively be used for acute liver failure in cardiopulmonary failure patients who are being supported by
ECMO in order to accelerate liver recovery.

Survival benefit by MARS was clearly demonstrated,

without any additional increase in complications.
Financial Conflict of Interest Disclosure
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Table 1: Inclusion Criteria for MARS on ECMO.

Hyperbilirubinemia (>10mg/dl)
Increased ALT (>1000 IU/L)
Hyperbilirubinemia (>10mg/dl) and increased ALT (>1000 IU/L)
ALT: alanine aminotransferase.

Data expressed as number.

Group M
(N=14)
11
3
4

Group C
(N=14)
14
0
2

P - value
0.0668
0.0668
0.3570
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Table 2: Baseline Demographics and Indications for ECMO.
Group M (n=14)

Group C (n=14)

P- value

44 ± 16
5 (36%)
27 ± 6
76 ± 26

54 ± 13
9 (64%)
28 ± 5
78 ± 21

0.0811
0.1306
0.6359
0.8246

5 (36%)
3 (21%)
4 (29%)
4 (29%)
3 (21%)

3 (21%)
2 (14%)
4 (29%)
8 (57%)
1 (7%)

0.4028
0.6217
1.0000
0.1266
0.2801

3 (21%)

4 (29%)

0.6625

Acute on chronic heart failure

4 (29%)

3 (21%)

0.6625

Malignant Arrhythmia

2 (14%)

0 (0%)

0.1422

Takotsubo Cardiomyopathy

0 (0%)

2 (14%)

0.1422

Bacterial Pneumonia

0 (0%)

1 (7%)

0.3085

Interstitial Pneumonitis

1 (7%)

0 (0%)

0.3085

Aspiration Pneumonia

0 (0%)

2 (14%)

0.1422

Viral Pneumonia

0 (0%)

1 (7%)

0.3085

Post-cardiotomy failure

5 (35%)

4 (29%)

0.6857

2 (14%)

1 (7%)

0.5412

1.7 ± 1
2.9 ± 3.1
3198 ± 9997
770 ± 1884
139 ± 100
7.4 ± 7.5
1.99 ± 1.10

1.8 ± 0.99
3.3 ± 3.2
784 ± 1610
351 ± 751
107 ± 78
6.6 ± 5.2
1.98 ± 0.89

0.7522
0.7611
0.3984
0.4642
0.3704
0.7521
0.9589

11 (79%)
3 (21%)
17 ± 9

11 (79%)
3 (21%)
12 ± 10

1.0000
1.0000
0.1761

10 (71%)
2 (14%)

11 (79%)
3 (21%)

0.6625
0.6217

Age (years)
Male
Body mass index (kg/m2)
Weight (kg)
Clinical risk factors
Smoker
E-CPR
Diabetes mellitus
Coronary artery disease
Acute myocardial infarction
Primary respiratory failure
Primary Diagnosis for ECMO

Acute Myocardial Infarction
Pre ECMO laboratory data
Creatinine (mg/dl)
Total bilirubin (mg/dl)
Aspartate aminotransferase (IU/L)
Alanine aminotransferase (IU/L)
Alkaline phosphatase (IU/L)
Lactate (mg/dl)
INR
ECMO data
Veno-arterial ECMO
Veno-venous ECMO
Length of ECMO (days)
ECMO complications
Bleeding
Disseminated intravascular coagulopathy
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DIC: disseminated intravascular coagulopathy; E-CPR: extra-corporeal membrane oxygenation assisted
cardiopulmonary resuscitation; ECMO: extra-corporeal membrane oxygenation; INR: international
normalized ratio
Data are expressed as mean ± standard deviation or as number (percentage).
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Table 3. Laboratory Data at Inclusion.

Duration of ECMO before MARS in group M and
before met criteria of acute liver failure in group C
(days)
On CVVHD pre-MARS
Creatinine (mg/dl)
Bilirubin (mg/dl)
Aspartate aminotransferase (IU/L)
Alanine aminotransferase (IU/L)
Alkaline phosphatase (IU/L)
Lactate (mg/dl)
INR
MELD Score

Group M
(N=14)

Group C
(N=14)

P-value

5±4

7±6

0.31

6 (43%)
1.3 ± 0.5
10.5 ± 3.3
9412 ± 13430
2271 ± 2577
162 ± 83
8.2 ± 8.0
1.86 ± 0.57
29 ± 6

9 (64%)
1.3 ± 0.7
11.8 ± 1.9
492 ± 698
193 ± 210
113 ± 47
6.8 ± 7.5
1.52 ± 0.43
30 ± 5

0.2556
1.0000
0.2128
0.0199
0.0058
0.0656
0.6369
0.0865
0.6359

CVVHD: continuous veno-veno hemodialysis; ECMO: extra-corporeal membrane oxygenation; INR:
international normalized ratio; MARS: molecular adsorbent recirculating system; MELD Score: Model
for End-Stage Liver Disease Score.
Data expressed as mean ± standard deviation or as number (percentage).
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Legends of Figures
Figure 1:

1a) Trends of total bilirubin; 1b) Trends of alanine aminotransferase (ALT); 1c) Trends of
international normalized ratio (INR).

Figure 2:

2a) Trends of total bilirubin in Group M; 2b) Trends of alanine aminotransferase (ALT) in
Group M; 2c) Trends of international normalized ratio (INR) in Group M.

Figure 3:

Survival data.
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